{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:09:25Z","timestamp":1790179765040,"version":"4.1.0"},"reference-count":37,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.2967\/jnumed.125.270568","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T20:25:20Z","timestamp":1763670320000},"page":"113-118","source":"Crossref","is-referenced-by-count":5,"title":["Claudin 18.2 as a Biomarker for Imaging and Radiopharmaceutical Therapy in Gastric and Pancreatic Tumors"],"prefix":"10.2967","volume":"67","author":[{"given":"Shvan J.","family":"Raheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Bashyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvin","family":"Haj-Mirzaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Khazaei Monfared","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Larimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi A.","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2026010206300909000_67.1.113.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026010206300909000_67.1.113.2","doi-asserted-by":"crossref","first-page":"104197","DOI":"10.1016\/j.critrevonc.2023.104197","article-title":"Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer","volume":"198","author":"Wang","year":"2024","journal-title":"Crit Rev Oncol Hematol."},{"key":"2026010206300909000_67.1.113.3","doi-asserted-by":"crossref","first-page":"17154","DOI":"10.1038\/s41598-023-44117-3","article-title":"Comparison of adjuvant capecitabine plus oxaliplatin (CAPOX) versus S-1 after gastrectomy: a population-based cohort study using a nationwide claims database","volume":"13","author":"Maeng","year":"2023","journal-title":"Sci Rep."},{"key":"2026010206300909000_67.1.113.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01518-1"},{"key":"2026010206300909000_67.1.113.5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3390\/jcm12072636","article-title":"Updated immunotherapy for gastric cancer","volume":"12","author":"Narita","year":"2023","journal-title":"J Clin Med."},{"key":"2026010206300909000_67.1.113.6","doi-asserted-by":"crossref","first-page":"1371421","DOI":"10.3389\/fonc.2024.1371421","article-title":"Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer","volume":"14","author":"Xu","year":"2024","journal-title":"Front Oncol."},{"key":"2026010206300909000_67.1.113.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00874-2"},{"key":"2026010206300909000_67.1.113.8","doi-asserted-by":"crossref","first-page":"e1523096","DOI":"10.1080\/2162402X.2018.1523096","article-title":"Characterization of zolbetuximab in pancreatic cancer models","volume":"8","author":"T\u00fcreci","year":"2019","journal-title":"Oncoimmunology."},{"key":"2026010206300909000_67.1.113.9","doi-asserted-by":"crossref","first-page":"155145","DOI":"10.1016\/j.prp.2024.155145","article-title":"Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion","volume":"254","author":"Angerilli","year":"2024","journal-title":"Pathol Res Pract."},{"key":"2026010206300909000_67.1.113.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68411-w"},{"key":"2026010206300909000_67.1.113.11","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v14.i7.1252"},{"key":"2026010206300909000_67.1.113.12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28400"},{"key":"2026010206300909000_67.1.113.13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12964-023-01406-8","article-title":"Claudin-18.2 mediated interaction of gastric cancer cells and cancer-associated fibroblasts drives tumor progression","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun Signal."},{"key":"2026010206300909000_67.1.113.14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00620-7"},{"key":"2026010206300909000_67.1.113.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7"},{"key":"2026010206300909000_67.1.113.16","first-page":"e75206","article-title":"Zolbetuximab for unresectable and metastatic gastric and gastroesophageal junction adenocarcinoma: a review of literature","volume":"16","author":"Samanta","year":"2024","journal-title":"Cureus."},{"key":"2026010206300909000_67.1.113.17","first-page":"64","article-title":"Claudin18.2-targeted cancer theranostics","volume":"13","author":"Zhang","year":"2023","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"2026010206300909000_67.1.113.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0546-8"},{"key":"2026010206300909000_67.1.113.19","unstructured":"Pancreas tissue gene expression data. GTREx Portal website. https:\/\/gtexportal.org\/home\/tissue\/Pancreas. Accessed February 20, 2025."},{"key":"2026010206300909000_67.1.113.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01157-1"},{"key":"2026010206300909000_67.1.113.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0414-6"},{"key":"2026010206300909000_67.1.113.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0591-3"},{"key":"2026010206300909000_67.1.113.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265391"},{"key":"2026010206300909000_67.1.113.24","doi-asserted-by":"crossref","first-page":"eadn7218","DOI":"10.1126\/scitranslmed.adn7218","article-title":"Development of a fibrin-targeted theranostic for gastric cancer","volume":"16","author":"Esfahani","year":"2024","journal-title":"Sci Trans Med."},{"key":"2026010206300909000_67.1.113.25","doi-asserted-by":"crossref","first-page":"20806","DOI":"10.1021\/acs.inorgchem.3c02714","article-title":"DFO-Km: a modular chelator as a new chemical tool for the construction of zirconium-89-based radiopharmaceuticals","volume":"62","author":"Salih","year":"2023","journal-title":"Inorg Chem."},{"key":"2026010206300909000_67.1.113.26","first-page":"52521","article-title":"The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies","volume":"12","author":"Zeglis","year":"2015","journal-title":"J Vis Exp."},{"key":"2026010206300909000_67.1.113.27","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/cas.15684","article-title":"Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma","volume":"114","author":"Shitara","year":"2023","journal-title":"Cancer Sci."},{"key":"2026010206300909000_67.1.113.28","unstructured":"Astellas to present positive findings from phase 3 SPOTLIGHT trial of zolbetuximab during 2023 ASCO GI Cancers Symposium. PR Newswire website. https:\/\/www.prnewswire.com\/news-releases\/astellas-to-present-positive-findings-from-phase-3-spotlight-trial-of-zolbetuximab-during-2023-asco-gi-cancers-symposium-301725409.html. Published January 19, 2023. Accessed October 29, 2025."},{"key":"2026010206300909000_67.1.113.29","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1021\/acs.molpharmaceut.4c00122","article-title":"Preparation of radiolabeled zolbetuximab targeting CLDN18.2 and its preliminary evaluation for potential clinical applications","volume":"21","author":"Wang","year":"2024","journal-title":"Mol Pharm."},{"key":"2026010206300909000_67.1.113.30","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1021\/acs.molpharmaceut.4c00155","article-title":"Molecular SPECT\/CT profiling of claudin18.2 expression in\u00a0vivo: implication for patients with gastric cancer","volume":"21","author":"Wu","year":"2024","journal-title":"Mol Pharm."},{"key":"2026010206300909000_67.1.113.31","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1021\/acs.molpharmaceut.4c01427","article-title":"Targeted radionuclide therapy of CLDN18.2-positive gastric cancer with [131I]I-zolbetuximab: an in\u00a0vitro and in\u00a0vivo study","volume":"22","author":"Wang","year":"2025","journal-title":"Mol Pharm."},{"key":"2026010206300909000_67.1.113.32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jpha.2023.02.011","article-title":"Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors","volume":"13","author":"Chen","year":"2023","journal-title":"J Pharm Anal."},{"key":"2026010206300909000_67.1.113.33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00259-023-06561-1","article-title":"[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models","volume":"51","author":"Zeng","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300909000_67.1.113.34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/IJN.S501689","article-title":"Utility of 131I-HLX58-Der for the precision treatment: evaluation of a preclinical radio-antibody-drug-conjugate approach in mouse models","volume":"20","author":"Liu","year":"2025","journal-title":"Int J Nanomedicine."},{"key":"2026010206300909000_67.1.113.35","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1007\/s00259-022-05739-3","article-title":"Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study","volume":"49","author":"Hu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300909000_67.1.113.36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.omto.2022.11.003","article-title":"Development and comparison of 68Ga\/18F\/64Cu-labeled nanobody tracers probing claudin18.2","volume":"27","author":"Wei","year":"2022","journal-title":"Mol Ther Oncolytics."},{"key":"2026010206300909000_67.1.113.37","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdx367.012","article-title":"Preclinical characterization of IMAB362 for the treatment of gastric carcinoma [abstract]","volume":"28","author":"Mitnacht-Kraus","year":"2017","journal-title":"Ann Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:31:01Z","timestamp":1767364261000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.2967\/jnumed.125.270568"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270568","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}